X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
male (25) 25
index medicus (24) 24
humans (23) 23
oncology (19) 19
aged (15) 15
pharmacology & pharmacy (13) 13
female (12) 12
chemotherapy (11) 11
middle aged (11) 11
oxidative stress (11) 11
aged, 80 and over (10) 10
animals (10) 10
adult (9) 9
antioxidants (8) 8
cancer (8) 8
docetaxel (8) 8
treatment outcome (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
capecitabine (7) 7
elderly (7) 7
oxidative stress - drug effects (7) 7
care and treatment (6) 6
cisplatin (6) 6
fluorouracil - administration & dosage (6) 6
gastric cancer (6) 6
neoplasm metastasis (6) 6
prostate cancer (6) 6
adenocarcinoma - drug therapy (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
apoptosis (5) 5
clinical-trials (5) 5
drug administration schedule (5) 5
glutathione (5) 5
glutathione-peroxidase (5) 5
malondialdehyde (5) 5
medicine & public health (5) 5
rats (5) 5
therapy (5) 5
toxicity (5) 5
1st-line treatment (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
cytokines (4) 4
deoxycytidine - administration & dosage (4) 4
deoxycytidine - analogs & derivatives (4) 4
disease-free survival (4) 4
dose-response relationship, drug (4) 4
double-blind (4) 4
drug therapy (4) 4
epirubicin (4) 4
fluorouracil - adverse effects (4) 4
gemcitabine (4) 4
glutathione - metabolism (4) 4
increased survival (4) 4
lipid peroxidation (4) 4
metastasis (4) 4
multicenter (4) 4
myocardium - metabolism (4) 4
neoplasm staging (4) 4
oxaliplatin (4) 4
phase-ii trial (4) 4
stomach neoplasms - drug therapy (4) 4
survival rate (4) 4
time factors (4) 4
5-fluorouracil (3) 3
abiraterone acetate (3) 3
administration, oral (3) 3
antineoplastic agents - therapeutic use (3) 3
apoptosis - drug effects (3) 3
ascorbic acid - metabolism (3) 3
ascorbic-acid (3) 3
bevacizumab (3) 3
breast-cancer (3) 3
carboplatin (3) 3
carcinoma, non-small-cell lung - pathology (3) 3
cardiac oxidative stress (3) 3
cocaine (3) 3
colorectal cancer (3) 3
deoxycytidine - adverse effects (3) 3
dna-damage (3) 3
drug therapy, combination (3) 3
efficacy (3) 3
elderly-patients (3) 3
endothelial growth-factor (3) 3
epirubicin - administration & dosage (3) 3
fluorouracil (3) 3
fluorouracil - analogs & derivatives (3) 3
fluorouracil - therapeutic use (3) 3
glutathione disulfide - metabolism (3) 3
glutathione peroxidase (3) 3
heart (3) 3
immunohistochemistry (3) 3
immunotherapy (3) 3
infertility (3) 3
inflammation (3) 3
injury (3) 3
internal medicine (3) 3
lung neoplasms - pathology (3) 3
malondialdehyde - metabolism (3) 3
mdma (3) 3
mice (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 5/2015, Volume 75, Issue 5, pp. 941 - 947
Journal Article
Oxidative Medicine and Cellular Longevity, ISSN 1942-0900, 10/2019, Volume 2019, pp. 1 - 8
Resistin is an adipokine involved in inflammation and able to induce the expression of other proinflammatory cytokines. It is known that, in human semen,... 
MALE-INFERTILITY | LEUKOCYTOSPERMIA | OXIDATIVE STRESS | OBESITY | CYTOKINES | MALONDIALDEHYDE | INSULIN-RESISTANCE | DNA-DAMAGE | INTERLEUKIN-6 | EXPRESSION | CELL BIOLOGY | Plasma | Obesity | Oxidative stress | Cytokines | Laboratories | Sperm | Lipid peroxidation | Inflammation | Gene expression | Immunology | Infertility | Insulin resistance | TNF inhibitors | Tumor necrosis factor-TNF | Diabetes | Females | Apoptosis
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 2015, Volume 75, Issue 4, pp. 683 - 690
Journal Article
Medical Oncology, ISSN 1357-0560, 4/2015, Volume 32, Issue 4, pp. 1 - 7
The present study evaluated the efficacy and safety of cisplatin (Cis), gemcitabine (Gem) and bevacizumab (Bev), followed by maintenance treatment with Bev and... 
Pathology | Medicine & Public Health | Hematology | Gemcitabine | Lung cancer | Oncology | Internal Medicine | Maintenance | Cisplatin | Vinorelbine | Bevacizumab | PLUS CISPLATIN | PERFORMANCE STATUS | ANTI-VEGF | PLACEBO | CARBOPLATIN | PEMETREXED PLUS | TRIAL | SINGLE-AGENT | ONCOLOGY | 1ST-LINE THERAPY | ENDOTHELIAL GROWTH-FACTOR | Lung Neoplasms - drug therapy | Adenocarcinoma - pathology | Prognosis | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Induction Chemotherapy | Lung Neoplasms - pathology | Male | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Vinblastine - analogs & derivatives | Aged, 80 and over | Adult | Female | Carcinoma, Non-Small-Cell Lung - pathology | Bevacizumab - administration & dosage | Administration, Oral | Deoxycytidine - administration & dosage | Survival Rate | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Antimitotic agents | Care and treatment | Chemotherapy | Neurosciences | Oncology, Experimental | Lung cancer, Small cell | Research | Lung cancer, Non-small cell | Antineoplastic agents | Cancer | Index Medicus
Journal Article
Journal of Cellular and Molecular Medicine, ISSN 1582-1838, 01/2007, Volume 11, Issue 1, pp. 156 - 170
Background: To investigate the cardiotoxic role of reactive oxygen species (ROS) and of products derived from catecholamines auto‐oxidation, we studied: (1)... 
norepinephrine | β1‐adrenergic receptors | cytokines | cardiac antioxidant cellular defence system | Cardiac antioxidant cellular defence system | Norepinephrine | Cytokines | adrenergic receptors | MEDICINE, RESEARCH & EXPERIMENTAL | APOPTOSIS | GLUTATHIONE-PEROXIDASE | REPERFUSION INJURY | CATECHOLAMINES | ISCHEMIA | beta-adrenergic receptors cytokines | FREE-RADICALS | CELL BIOLOGY | PERFORMANCE LIQUID-CHROMATOGRAPHY | HEART | PATHWAY | TNF-ALPHA | Immunohistochemistry | Norepinephrine - pharmacology | Reactive Oxygen Species - metabolism | Rats, Wistar | Apoptosis - drug effects | Glutathione Reductase - metabolism | Norepinephrine - administration & dosage | Male | Glutathione Disulfide - metabolism | Malondialdehyde - analysis | Adrenergic alpha-Agonists - administration & dosage | Myocardium - metabolism | Lipid Peroxidation - drug effects | Electrocardiography | Superoxide Dismutase - metabolism | Glutathione Peroxidase - metabolism | Cytokines - metabolism | Drug Administration Schedule | Rats | Myocardium - pathology | Receptors, Adrenergic, beta-1 - metabolism | Myocardium - enzymology | Animals | Adrenergic alpha-Agonists - pharmacology | Oxidative Stress - drug effects | Receptor Cross-Talk - drug effects | Heart | Oxidative stress | Reductases | Cardiac arrhythmia | Reactive oxygen species | Pathogenesis | Lipid peroxidation | Superoxide dismutase | Interleukin 6 | Proteins | Antioxidants | Receptors | Interleukins | Glutathione reductase | Interleukin 1 | Tumor necrosis factor-TNF | Oxidation | Peroxidase | Interleukin 8 | Glutathione | Glutathione peroxidase | EKG | Free radicals | Cardiomyocytes | Catecholamines | Malondialdehyde | Intermediates | Monocytes | Tumor necrosis factor | Morphology | Interleukin 10 | Myocardium | Adrenergic receptors | Laboratory animals | Receptors (physiology) | Apoptosis | Reductase | β1-adrenergic receptors
Journal Article
Toxicology and Applied Pharmacology, ISSN 0041-008X, 10/2014, Volume 280, Issue 1, pp. 97 - 106
Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 6/2011, Volume 16, Issue 3, pp. 264 - 269
The aim of this study was to assess the early effects of zoledronic acid (ZOL) and oral ibandronate (IBA) on the bone resorption marker s-CTX (serum... 
Diagnostic Radiology | NSCLC | Internal Medicine | Oncology | Breast cancer | Radiotherapy | Zoledronate | Bone markers | Bone metastases | Pathology | Medicine & Public Health | Ibandronate | Surgical Oncology | Prostate cancer | RESORPTION | SOLID TUMORS | PHASE-III | SKELETAL COMPLICATIONS | BREAST-CANCER | BISPHOSPHONATES | ONCOLOGY | PROSTATE-CANCER | CLINICAL-TRIALS | DISEASE | PAIN QUESTIONNAIRE | Injections, Intravenous | Humans | Middle Aged | Alkaline Phosphatase - metabolism | Bone Neoplasms - secondary | Imidazoles - administration & dosage | Lung Neoplasms - pathology | Male | Bone Remodeling - drug effects | Bone Neoplasms - metabolism | Carcinoma, Non-Small-Cell Lung - secondary | Peptides - metabolism | Biomarkers, Tumor - metabolism | Female | Bone Resorption - chemically induced | Bone Neoplasms - drug therapy | Diphosphonates - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Collagen Type I - metabolism | Bone Density Conservation Agents - adverse effects | Administration, Oral | Imidazoles - adverse effects | Carcinoma, Non-Small-Cell Lung - metabolism | Bone Density Conservation Agents - therapeutic use | Treatment Outcome | Diphosphonates - administration & dosage | Aged | Care and treatment | Phosphatases | Analysis | Collagen | Oncology, Experimental | Phosphonates | Metastasis | Research | Lung cancer, Non-small cell | Cancer
Journal Article
Clinical Colorectal Cancer, ISSN 1533-0028, 12/2018, Volume 17, Issue 4, pp. 307 - 312
Regorafenib was shown to improve survival of patients with metastatic colorectal cancer resistant or unfit for all available therapies. Data on the efficacy... 
Regorafenib | Geriatric assessment | Elderly | Metastatic cancer | Colorectal cancer | MULTICENTER | CONSENSUS | COLON | SOCIETY | CARE | TARGETED THERAPIES | ONCOLOGY | PHASE-3 TRIAL | Aged | Drug therapy | Health aspects
Journal Article
Expert Review of Gastroenterology & Hepatology, ISSN 1747-4124, 08/2016, Volume 10, Issue 8, pp. 887 - 892
Journal Article